Here are some of the slides from the BioAge presentation at the Longevity Summit in December last year. BioAge raised over $200 Million in their IPO a little over a year ago.
There are a number of companies working on clinical trials for NLRP3 inhibitors (and these are expected to be important longevity drugs in the future if they pass phase 3 clinical trials). Another company working in this area is discussed here: The Immuno-Neuro Dialogue: A 5-Point Playbook for Rewiring the Aging Brain - #3 by RapAdmin
Note: You can click on any image below to make it larger and then you can move through the entire presentation with just your arrow keys.
